GSK’s new asthma drug Relvar Ellipta has shown itself to be superior to existing treatments in a major real world trial, the Salford Lung Study (SLS). Developed with US respiratory specialist firm ...
After some disappointing earlier results for GSK’s new asthma treatment Revlar Ellipta, the company has today announced some encouraging news. An open-label non-inferiority lung function study has ...
Chart does not reflect overnight price.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback